Sungkwang Medical Foundation

Cmg Pharmaceutical Co., Ltd.

Hee Jung An

Yong Wha Moon

Ah Young Kwon

Yeon Ho Choi

Eun Jin Lim

Se Wha Kim

Jin Sung Kim

Albert Charles Gyorkos

Eun Kyung Choi

Jeongbeob Seo

Suk Young Cho

Gilnam Lee

Jung Jin Hwang

Choung Soo Kim

Han Won Cho

Chul Soo Lim

Tae Heon Kim

Hae Youn Kang

Provided are a composition for culturing NK cells, and a method of culturing NK cells using the same. According to an aspect, in culturing NK cells from peripheral blood mononuclear cells, when NK cells are cultured in a medium including the composition for culturing NK cells, the composition including IL-15, IL-18, and IL-27, the NK cells may proliferate in large quantities and activation of NK cells may be promoted. Therefore, when the NK cells are used, cancer cell apoptosis or cancer cell-killing ability may be promoted. Accordingly, the NK cells may be used as an effective adoptive immune cell therapy product in cancer prevention or treatment.

Composition for culturing NK cells and method for culturing NK cells using same

According to a composition, kit, and method for diagnosing resistance to a taxane anticancer agent, a composition for treating taxane cancer agent-resistant cancers, and a method for screening materials for the same, taxane anticancer agent-resistant cancers may be efficiently diagnosed or treated, and candidate materials that may treat taxane anticancer agent-resistant cancers may be efficiently screened.

Composition, kit, and method for diagnosis and treatment of taxane anticancer agent-resistant cancer

Provided are a composition, a kit, and a method of predicting prognosis of ovarian cancer or a risk of recurrence of ovarian cancer. Provided are a composition for treating ovarian cancer or preventing recurrence of ovarian cancer and a method of screening a material for treating ovarian cancer or preventing recurrence of ovarian cancer. According to the present disclosure, prognosis or recurrence of ovarian cancer can be efficiently diagnosed, and a candidate material that can treat ovarian cancer or prevent recurrence of ovarian cancer can be efficiently screened.

Method for diagnosing and treating ovarian cancer

Composition, kit, and method for diagnosing and treating ovarian cancer

The invention provides novel substituted pyridopyrimidines represented by Formula I or a pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof, and a composition comprising these compounds. The compounds provided can be used as inhibitors of the phosphoinositide 3' OH kinase family (PI3K) for the treatment of inflammatory diseases, cancer, cardiovascular diseases, allergy, asthma and autoimmune disorders. 

Pyridopyrimidine derivatives and use thereof

Growing community of inventors

Seoul, South Korea

Hee Jung An